Group 1 - The company, Tonghua Golden Horse, plans to invest RMB 70 million to establish a wholly-owned subsidiary named Guilin Jinma Innovation Investment Co., Ltd. [1] - The investment is aligned with the company's overall strategic planning and research and development needs [1] - The name of the subsidiary is provisional and will be confirmed by the relevant administrative authorities [1]

Core Insights - Hainan Haiyao reported that as of October 31, 2025, the number of shareholders is 75,607 [2] Company Summary - The company is actively engaging with investors through interactive platforms [2] - The increase in shareholder count may indicate growing investor interest and confidence in the company [2]

Market Overview - The chemical pharmaceutical sector experienced a slight decline of 0.01% on November 6, with Sunflower leading the losses [1] - The Shanghai Composite Index closed at 4007.76, up 0.97%, while the Shenzhen Component Index closed at 13452.42, up 1.73% [1] Stock Performance - Notable gainers in the chemical pharmaceutical sector included: - Tonghua Golden Horse (000766) with a closing price of 28.19, up 4.80% on a trading volume of 261,300 shares and a turnover of 717 million yuan [1] - Fuxiang Pharmaceutical (300497) closed at 11.28, up 4.54% with a trading volume of 334,700 shares and a turnover of 373 million yuan [1] - Xintai (002294) closed at 60.28, up 4.40% with a trading volume of 58,000 shares and a turnover of 343 million yuan [1] - Conversely, significant decliners included: - Sunflower (300111) closed at 8.41, down 7.99% with a trading volume of 2,044,500 shares and a turnover of 174.6 million yuan [2] - Shutaishen (300204) closed at 34.72, down 6.62% with a trading volume of 540,800 shares and a turnover of 186.8 million yuan [2] - Bibet (688759) closed at 32.13, down 5.14% with a trading volume of 105,800 shares and a turnover of 344 million yuan [2] Capital Flow - The chemical pharmaceutical sector saw a net outflow of 1.177 billion yuan from institutional investors, while retail investors contributed a net inflow of 796 million yuan [2] - The capital flow for specific stocks indicated: - Haichen Pharmaceutical (300584) had a net inflow of 71.88 million yuan from institutional investors [3] - Renfu Pharmaceutical (600079) experienced a net outflow of 14.39 million yuan from institutional investors [3] - Tonghua Golden Horse (000766) had a net inflow of 47.58 million yuan from institutional investors [3]

Core Viewpoint - Haizheng Pharmaceutical (600267.SH) has received approval from the Ministry of Agriculture and Rural Affairs of the People's Republic of China for its veterinary drug products, which will enhance its product line and market competitiveness in the veterinary sector [1] Group 1 - Haizheng Pharmaceutical's subsidiary, Zhejiang Haizheng Animal Health Products Co., Ltd., has obtained approval for the compound griseofulvin ointment and torasemide suspension veterinary drug products [1] - The approval will enrich the company's veterinary drug product line and structure [1] - This development is expected to further promote the company's strategic layout in the veterinary drug sector [1]

Core Viewpoint - The company, Jianyou Co., Ltd. (603707.SH), has received approval from the National Medical Products Administration (NMPA) for its sodium heparin injection products, indicating a successful completion of the consistency evaluation for generic drug quality and efficacy [1] Group 1: Product Approval - The NMPA has issued a notification for the approval of sodium heparin injection in two dosages: 0.3ml with 3075AⅩaIU and 0.6ml with 6150AⅩaIU [1] - The approved product is intended for use in surgical procedures to prevent venous thromboembolism in patients at moderate to high risk of venous thrombus formation [1] Group 2: Clinical Applications - Sodium heparin injection is used for the treatment of established deep vein thrombosis and in combination with aspirin for unstable angina and non-Q-wave myocardial infarction during the acute phase [1] - The product is also utilized in hemodialysis to prevent clot formation during extracorporeal circulation [1]

Core Viewpoint - The company, Jianyou Co., Ltd. (603707.SH), has received approval from the National Medical Products Administration (NMPA) for its product, Nadroparin Calcium Injection, indicating a successful completion of the consistency evaluation for generic drug quality and efficacy [1] Group 1: Product Approval - The NMPA has issued a supplemental application approval notice for Nadroparin Calcium Injection in two dosages: 0.3ml (3075AⅩaIU) and 0.6ml (6150AⅩaIU) [1] - The product is approved for use in preventing venous thromboembolism in patients at moderate to high risk during surgical procedures [1] - It is also indicated for the treatment of established deep vein thrombosis and in combination with aspirin for unstable angina and non-Q wave myocardial infarction in the acute phase [1] Group 2: Clinical Applications - Nadroparin Calcium Injection is utilized in hemodialysis to prevent clot formation during extracorporeal circulation [1]

Core Viewpoint - Fuxiang Pharmaceutical successfully passed the FDA's cGMP inspection, indicating its compliance with international quality standards and enhancing its capability to supply commercial intermediates and APIs to the US and global markets [1] Group 1: FDA Inspection Results - The company underwent an FDA cGMP inspection from August 11 to August 14, 2025, covering various GMP systems including quality management, material management, production management, equipment facilities, packaging and labeling, and laboratory control [1] - The inspection resulted in a VAI (Voluntary Action Indicated) outcome, marking the third successful cGMP inspection by the FDA for the company [1] Group 2: Implications for the Company - The successful inspection reflects the company's commitment to high international quality standards and validates the effective operation of its management system [1] - This achievement is expected to boost the company's competitiveness and support its goals for international market expansion [1]

Core Viewpoint - Fuxiang Pharmaceutical successfully passed the FDA's cGMP inspection, indicating its compliance with international quality standards and enhancing its capability to supply commercial intermediates and APIs to the US and global markets [1] Group 1: FDA Inspection Results - The company underwent an FDA cGMP inspection from August 11 to August 14, 2025, covering various GMP systems including quality, material management, production, equipment, packaging, labeling, and laboratory control [1] - The inspection resulted in a VAI (Voluntary Action Indicated) outcome, marking the third successful cGMP inspection by the FDA for the company [1] Group 2: Implications for the Company - The successful inspection reflects the company's commitment to high international quality standards and validates the effective operation of its management systems [1] - This achievement is expected to boost the company's competitiveness and support its goals for international market expansion [1]

Core Insights - The company successfully passed a cGMP inspection by the FDA from August 11 to August 14, 2025, covering various quality and management systems [1] - This marks the third successful cGMP inspection by the FDA, indicating the company's quality systems are aligned with international standards [1] - The successful inspection qualifies the company to continuously provide commercial intermediates and active pharmaceutical ingredients for the U.S. and global markets [1]

Core Viewpoint - Fuxiang Pharmaceutical successfully passed the FDA's cGMP inspection, indicating its compliance with international quality standards and enhancing its capability to supply commercial intermediates and APIs to the US and global markets [1] Group 1: FDA Inspection Results - The company underwent an FDA cGMP inspection from August 11 to August 14, 2025, covering various GMP systems including quality, material management, production, equipment, packaging, labeling, and laboratory control [1] - The inspection resulted in a VAI (Voluntary Action Indicated) outcome, marking the third successful cGMP inspection by the FDA for the company [1] Group 2: Implications for the Company - The successful inspection reflects the company's commitment to high international quality standards and validates the effective operation of its management systems [1] - This achievement is expected to boost the company's competitiveness and support its goals for international market expansion [1]